

IR BOOK_(Finance)

THE INVESTOR RELATIONS OF CLASSYS 2026

13 May 2026

Disclaimer



This material has been prepared by Classys (the "company") for the purpose of providing information in a presentation that will be made for investors. Please be informed that transferring, copying, or re-distributing this document to others is prohibited.

Attendance at this presentation is considered as your agreement to comply with the above-mentioned restrictions, and violation of these restrictions may be regarded as a violation of the Financial Investment Services and Capital Markets Act of South Korea.

The forward-looking statements included herein are unverified and pertains to future events related to the company's expected future financial performance, and are expressed with words such as 'forecast,' 'prospect,' 'expectation,' 'outlook' and '(E).'

Despite being made in good faith based on reasonable grounds or assumptions by management, such "forward-looking statements" are subject to various influences, including changes in future business environments, and inherently contain uncertainties. As a result, actual future performance may significantly differ from the information stated or implied in the forward-looking statements.

Additionally, the future outlook is based on the information available at the time of the presentation and is subject to change based on future market developments and changes in the Company's strategic direction without prior notice.

The company and its executives do not assume any responsibility for losses incurred through the use of this document (including negligence and other cases).

This document does not constitute a solicitation for placement, sales, trading or subscription of stocks. No part of this document should be considered as a basis or ground for related contracts, agreements, or investment decisions. All investment decisions related to stock purchases should be made solely based on investors' reasonable judgment.

1Q26 Financial Results

- Key Highlights
- Profit & Loss
- Sales by Brand
- SG&A
- Financial Position

Key Highlights

Acquisition Completed in **South America** on March 5

Temporary unrealized profit elimination impact expected to ease, with full-quarter contribution
Expected margin improvement through enhanced AR management and financial structure optimization

Strengthening **European** Presence

Full-spectrum EBD portfolio sales growth with increasing consumables contribution

Leading the **U.S.** RF Market

Brand expansion of Everesse and RF portfolio diversification with Quadessy launch

China GTM Strategy Underway

Completed market assessment and local partner sourcing in progress

1. Profit & Loss

(KRW bn)

consolidated basis	1Q26	1Q25	YoY	4Q25	QoQ
Revenue	87.2	77.1	+13.0%	93.4	-6.7%
COGS	(22.1)	(15.8)	+40.2%	(21.4)	+3.4%
(%)	25.4%	20.5%	+4.9%p	22.9%	+2.5%p
Gross profit	65.0	61.3	+6.1%	72.0	-9.7%
(%)	74.6%	79.5%	-4.9%p	77.1%	-2.5%p
SG&A	(27.8)	(22.5)	+23.5%	(20.8)	+33.7%
(%)	31.9%	29.2%	+2.7%p	22.3%	+9.6%p
Operating profit	37.2	38.8	-4.1%	51.2	-27.3%
(%)	42.7%	50.3%	-7.6%p	54.8%	-12.1%p
Financial Income	10.2	2.1	+378.3%	4.7	+118.8%
Financial Expenses	(2.4)	(1.4)	+71.8%	(0.9)	+160.9%
Other Income	0.5	0.0	+1034.0%	0.3	+102.2%
Other Expenses	(0.7)	(0.0)	+29276.5%	(0.9)	-22.7%
Pre-Tax Income	44.8	39.6	+13.4%	54.3	-17.5%
Tax Expenses	(11.7)	(9.8)	+19.0%	(11.7)	-0.3%
Net Income	33.6	29.8	+12.7%	42.6	-21.2%
(%)	38.6%	38.7%	-0.1%p	45.6%	-7.1%p
EBITDA	41.0	42.3	-3.0%	54.9	-25.2%
(%)	47.1%	54.9%	-7.8%p	58.7%	-11.7%p

2025	2024	2023
336.8	242.9	180.1
(75.7)	(51.8)	(39.7)
22.5%	21.3%	22.0%
261.1	191.1	140.4
77.5%	78.7%	78.0%
(90.5)	(68.7)	(50.8)
26.9%	28.3%	28.2%
170.6	122.4	89.6
50.7%	50.4%	49.8%
10.1	24.2	8.7
(10.9)	(5.7)	(4.3)
0.4	0.0	0.0
(1.6)	(12.0)	(0.2)
168.6	127.9	93.8
(36.7)	(30.4)	(19.6)
131.9	97.9	74.2
39.2%	40.3%	41.2%
185.2	129.7	93.9
55.0%	53.4%	52.1%

□ Revenue: KRW 87bn (YoY +13.0% QoQ -6.7%)

- 20 Consecutive YoY Growth Quarters
- Contribution from aesthetic EBD line-up expansion
- Infrastructure set for long-term growth in Brazil & Japan

□ Gross Profit: KRW 65bn (YoY +6.1%, QoQ -9.7%)

- Temporary impact from the elimination of unrealized profit associated with the initial consolidation closin, maintained strong margin thanks to cost optimization

Revenue Mix	1Q25	2Q25	3Q25	4Q25	1Q26
Devices	46%	55%	52%	54%	48%
Consumables	53%	42%	45%	44%	47%

□ Operating Profit: KRW 37bn (YoY -4.1%, QoQ -27.3%)

- Increased Marketing and M&A expenses for business expansion
- Base effect reflected from one-time reversal of bad debt expenses in 4Q25

□ Profitability Ratios

- Maintained strong levels
- 1Q26 OPM 42.7% / NIM 38.6 % / EBITDA Margin 47.1%

□ FX Rate

- Favorable FX impact on revenue and margins

KRW/USD	1Q25	2Q25	3Q25	4Q25	1Q26
Average	1,453	1,404	1,392	1,467	1,457
Period-end	1,467	1,356	1,402	1,435	1,513

(Note 1) If negative or expenses, shown in parentheses

This page has been prepared based on preliminary earnings results. Please refer to the official disclosures.

2. Sales by Brand

(KRW bn)

consolidated basis	1Q26	1Q25	YoY	4Q25	QoQ
Revenue	87.2	77.1	+13.1%	93.4	-6.7%
Legacy Business¹	85.4	77.1	+10.8%	93.4	-8.6%
Global	61.5	52.5	+17.1%	65.7	-6.5%
Korea	23.9	24.6	-2.8%	27.7	-13.6%
Device	42.1	35.1	+19.9%	50.5	-16.6%
Global	35.5	25.9	+37.1%	37.9	-6.4%
Korea	6.6	9.2	-28.3%	12.5	-47.3%
Consumables	40.9	41.0	-0.2%	41.1	-0.5%
Global	26.0	26.1	-0.4%	27.7	-6.2%
Korea	14.9	14.9	+0.0%	13.4	+11.2%
Homecare	2.2	0.8	+175.0%	1.6	+37.3%
Global	0.0	0.6	+0.0%	0.1	-100.0%
Korea	2.2	0.3	+633.3%	1.5	+44.5%
Rentals(Korea)	0.2	0.2	+0.0%	0.2	-15.6%
South America Adds²	1.8	0.0	+0.0%	0.0	+0.0%

2025	2024	2023
336.8	242.9	180.1
336.8	242.9	180.1
224.7	163.2	116.5
112.2	79.8	63.6
174.0	124.3	95.1
128.0	94.9	67.9
45.9	29.4	27.1
154.6	112.9	81.0
95.5	67.0	47.8
59.2	46.0	33.3
7.3	4.7	2.4
1.2	1.3	0.8
6.1	3.4	1.6
0.9	1.0	1.6
-	-	-

- **Consolidated Revenue: KRW 87bn (YoY +13.1% QoQ -6.7%)**
 - Scaling in Europe & U.S.; balanced growth in CIS & Thailand
 - Consumables expansion and new product contributions expected from 2Q in Korea
- **Devices: KRW 42bn (YoY +19.9% QoQ -16.6%)**
 - Health sales of Ultraformer + High growth of Volnewmer + New launch impact of Quadessy
 - Domestic laser demand adjustment with new products in ramp-up phase
- **Consumables: KRW 40bn (YoY -0.2% QoQ -0.5%)**
 - Stable revenue supported by increased utilization
 - Solid growth in Thailand, CIS, and Australia Excluding Brazil one-off effect
 - Strong revenue maintained in Korea
- **Homecare: KRW 2.2bn**
 - Steady growth in device sales
- **Rentals: KRW 0.2bn**
- **South America Consolidation**
 - Initiated: Brazil, Colombia, and Argentina
 - Growth Expected with Sufficient Inventory & sales activities
 - Establishing operational infrastructure in Colombia and Argentina

(Note1) Legacy Business: Classys HQ, Japan, U.S., China, NSON, (Note 2) South America Adds: Classys Brazil, Colombia, Argentina
Data classified based on 2025 business standards for investor understanding; please refer to the official disclosures.

3. SG&A

(KRW bn)

consolidated basis	1Q26	1Q25	YoY	4Q25	QoQ	2025	2024	2023
SG&A	27.8	22.5	+23.5%	20.8	+33.7%	90.5	68.7	50.8
(% of sales)	31.9%	29.2%		22.3%		26.9%	28.3%	28.2%
Salaries	4.5	3.9	+15.1%	3.9	+15.3%	15.7	12.5	9.7
(% of sales)	5.1%	5.0%		4.2%		4.6%	5.1%	5.4%
R&D	4.7	4.2	+13.2%	4.7	+0.4%	17.4	12.6	9.2
(% of sales)	5.4%	5.4%		5.0%		5.2%	5.2%	5.1%
Advertising	5.4	3.6	+49.6%	5.5	-0.1%	17.6	12.8	9.0
(% of sales)	6.2%	4.7%		5.8%		5.2%	5.3%	5.0%
Commissions	5.4	2.4	+127.8%	4.5	+19.4%	10.7	10.4	7.5
(% of sales)	6.2%	3.1%		4.8%		3.2%	4.3%	4.2%
D&A	2.8	2.6	+5.0%	2.8	-0.3%	10.9	4.7	2.2
(% of sales)	3.2%	3.4%		3.0%		3.2%	2.0%	1.2%
Sales commission	0.8	1.5	-49.3%	1.1	-31.6%	5.6	3.4	3.2
(% of sales)	0.9%	2.0%		1.2%		1.7%	1.4%	1.8%
Retirement benefits	0.3	0.3	-0.9%	0.3	+8.1%	1.0	0.9	0.7
(% of sales)	0.0%	0.0%		0.0%		0.0%	0.0%	0.0%
Others	4.0	4.0	-1.2%	(1.9)	-311.9%	11.6	11.3	9.3
(% of sales)	4.6%	5.2%		-2.0%		3.5%	4.6%	5.1%

■ SG&A: KRW 27bn (YoY +23.5%, QoQ +33.7%)

- Legacy Business SG&S 25bn, 29.9% of sales(yoy +0.7%p)
- Consolidation Impact: KRW 2.2bn (Incl. KRW 0.85bn in one-time acquisition advisory fees)

■ Salaries: KRW 4.5bn (YoY +15.1%, QoQ +15.3%)

Headcount	25.03	25.06	25.09	25.12	26.03
Headquarters	513	515	511	528	531
JL Health	-	-	-	-	206

■ R&D: KRW 4.7bn (YoY +13.2%, QoQ +0.4%)

- R&D/Clinical trials/Approval costs for new product and upgrade projects

■ Advertising: KRW 5.4bn (YoY +49.6%, QoQ -0.1%)

- Major events & B2C marketing (e.g., IMCAS in Jan, KIMES and User Meetings in Mar)
- Annual spend within planned budget

■ Commissions: KRW 5.4bn (YoY +127.8%, QoQ +19.4%)

- % of revenue declined

■ Depreciation/Amortization: KRW 2.8bn (YoY +5.0%, QoQ -0.3%)

- Recurring amortization of merger-related assets (Flat YoY)

■ Others: KRW 4.0bn (YoY -1.2%, QoQ -311.9%)

- Fixed G&A costs & Base effect from prior bad debt reversal

This page has been prepared based on preliminary earnings results. Please refer to the official disclosures.

4. Financial Position

(KRW bn)

consolidated basis	2023	2024	2025	2026.03
Assets	375.4	608.4	704.6	799.9
Current Assets	185.7	234.2	295.8	362.7
Cash & Cash Equivalents	136.9	158.0	207.6	181.7
Inventories	19.4	30.0	30.1	59.1
Account Receivables	17.3	36.9	48.4	108.6
Others	12.2	9.2	9.7	13.2
Non-current Assets	189.7	374.2	408.9	437.2
P.P.E	139.0	193.2	199.7	207.8
Investment Property	41.1	29.4	29.3	29.2
Intangible Assets	2.8	140.9	139.6	146.3
Others	6.8	10.6	40.3	53.9
Liabilities	91.9	155.7	153.0	270.5
Current Liabilities	29.2	128.9	80.2	252.3
Non-current Liabilities	62.7	26.8	72.8	18.2
Equity	283.5	452.6	551.7	529.3
Share Capital	6.5	6.6	6.6	6.6
Capital Surplus	24.2	106.3	9.9	9.9
Capital Adjustment	(18.3)	4.8	(11.3)	2.8
Other Comprehensive Income	0.1	0.1	0.2	0.5
Retained Earnings	271.0	336.1	547.5	501.9
Non-controlling Interest	0.0	(1.3)	(1.3)	7.5

□ Total Assets: KRW 799bn

■ Current Assets: KRW 362bn

- Cash & Cash Equivalents:
- Despite acquisition and tax settlements, solid OCF
- Inventories:
- Stabilization of HQ' CPS (Classsys Production System) and expanded Adoption at subsidiaries
- Accounts Receivable:
- Growth in Key Market Sales and Consolidation of Brazil local Receivables(KRW 54.51bn)

■ Non-current Assets: KRW 437bn

- PPE & Investment Properties: HQ, plant buildings, and Former Ilooda Industrial Facility
- Others: Elimination of Brazil internal loan Transactions, Consolidation of Brazil local long-term receivables(KRW 15.1bn)

□ Total Liabilities: KRW 270bn

■ Current Liabilities: KRW 252bn

- Temporary Increase and Reclassification Effects:
- KRW 82.6bn HQ Building Loan Reclassified as Current Liability (Planned to Refinance as Long-term)
- KRW 65.1bn Dividends Payable (Paid in April)
- KRW 23.7bn Income Tax Payable (Paid in April)
- Brazil: Consolidation of short-term borrowings (KRW 40.5bn); Restructuring under review

■ Non-current Liabilities: KRW 18bn

- Brazil: Consolidation of long-term borrowings (KRW 22bn)

□ Total Equity: KRW 529bn

(Note 1) Cash & Equivalents: Sum of Cash, Short-term Financial Instruments, and FVPL Financial Assets.
This page has been prepared based on preliminary earnings results. Please refer to the official disclosures.


Appendix

- Consolidation Impact from Classsys Brasil
- 2026 Guidance Roadmap
- Installed Base Expansion
- 2026 Guidance


Consolidation Impact from Classsys Brasil



1Q26 Gross Margin Bridge



2Q26(E) Profit & Loss Flow



(Note 1) This material has been prepared to aid understanding. Please refer to the disclosure materials for actual figures.

2026 Guidance Roadmap

On-track: 2026 Strategy for Product / Region / Channel Diversification

Mid-to-Long term

China Market Study

China Distributor Selection

China Local Partner Training

Volnewmer Approval in China

Key Driver

- **Launch of Quadessy**
 - USA & Thailand in March
- **Acquisition Completed**
 - 2026.03.04

- **New Brand Ramp-up in Korea**
 - Quadessy(MNRF), Fortra(Laser)
- **Accelerating Korea Marketing**
- **Full-quarter Contribution**
 - JL Health, MEDSYSTEMS AR, MEDSYSTEMS CO.
- **Expanding Brand Presence in EU**

- **Strengthening penetration**
 - Volnewmer
- **Expansion of procedures**
 - domestic & internation

- **Launch of Quadessy in Brazil**
- **Launch of Aquapure in Europe**
- **Expansion of package and combined treatment offerings**

1Q26

2Q26E


3Q26E

4Q26E

Full-year guidance supported by stepwise growth momentum


Installed Base Expansion

Dominating Aesthetic EBD Market & Accelerating Global Expansion



▲ Three-Month Sales Volume Increase

2026 Guidance



* Guidance Band : KRW 470 billion (yoy 40%) ~ KRW 510 billion (yoy 51%)

1

Direct Operations in Brazil, LATAM and Japan: “Enhancing Profit Structure”

- Revenue recognition based on end-user pricing, with margin capture
- Strengthened training and service, driving lock-in effects and accelerating market share expansion

2

US & Europe: “Scaled Growth”

- Accelerating adoption across key European markets
- Expanding RF leadership in the U.S. with Quadessy and Everesse, expecting 2027 Ultraformer approval

3

Volnewmer(Everesse): “Next Global Flagship”

- Entering a high-growth trajectory with annual unit sales exceeding 2,000
- Positioned as the next Flagship succeeding Ultraformer, which surpasses 3,000 units annually

4

Quadessy, Laser: “Next Gen. MNRF, First kind of Laser”

- Aiming to surpass 1,000 units annually as global rollout progresses
- Establishing Quadessy as a primary expansion driver in the MNRF category

5

Korea: “Leading the Combined-Procedure Trend”

- Combination procedure strategy across Volnewmer, Shrink Universe, and Fortra
- Accelerating procedure volume growth and utilization rates

6

Home Beauty: “B2C Revenue Leverage”

- Broadening retail and distribution footprint for Shrink Home Lift-to-Glow
- Enhancing B2C revenue contribution through continued portfolio expansion

7

China: “Market Entry”

- Distributor agreement; commercial rollout expected upon Volnewmer approval
- Positioned as a strategic long-term growth opportunity with Ultraformer



208, Teheran-ro, Gangnam-gu, Seoul

<http://www.classys.com> | +82-2-6313-2106

email: ir@classys.com